GlassScriptPhysician profile
Michelle A Liske
NPI 1326366121
$2,767.94
in general payments reported to CMS, 2019-2025
24 companies · $674 in 2025
The $674 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389 · 2020: $94.59 · 2021: $50.76 · 2022: $178 · 2023: $592 · 2024: $789 · 2025: $674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,055.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,054.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $712.74 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $312.36 | 2019-2025 | Evenity, Prolia, Prolia |
| Abbvie INC. | $293.02 | 2021-2025 | |
| Lilly USA, LLC | $280.81 | 2019-2025 | Mounjaro |
| Novo Nordisk INC | $266.47 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $171.76 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $160.47 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $75.64 | 2019-2025 | |
| Exact Sciences Corporation | $54.84 | 2024-2025 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $49.70 | 2019-2023 | Ajovy |
| Astellas Pharma US INC | $48.39 | 2019-2025 | Veozah |
| Boston Scientific Corporation | $47.59 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $39.81 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $37.14 | 2019-2023 | Steglatro, Belsomra |
| Vertex Pharmaceuticals Incorporated | $34.83 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $32.43 | 2025 | Symbravo |
| Biohaven Pharmaceuticals, INC. | $25.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.11 | 2025 | Gattex |
| Duchesnay USA Incorporated | $21.25 | 2019 | |
| Allergan, INC. | $18.57 | 2019 | |
| Daiichi Sankyo INC. | $17.17 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.82 | 2024 | Zoryve |
| Janssen Pharmaceuticals, INC | $14.61 | 2019 | |
| Philips North America LLC | $14.41 | 2024 | (Ck7) Extended Holter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Liske listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.